Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure

Background-Significant variation exists within the endothelial nitric oxide synthase (NOS3) gene that may influence cardiovascular risk. The Asp(298) variant of NOS3 has a shorter half-life in endothelial cells. Given the importance of nitric oxide in the heart failure syndrome, we evaluated the effect of this variant on event-free survival in a population with systolic dysfunction. Methods and Results-Four hundred sixty-nine patients (72% male, 49% ischemic; mean age, 56 +/- 12 years) with systolic dysfunction (left ventricular ejection fraction less than or equal to0.45) were enrolled in a study of Genetic Risk Assessment of Cardiac Events (GRACE). The polymorphism in exon 7 of NOS3, a G-T transition at position 894 that results in a Glu to Asp amino acid substitution for codon 298, was genotyped and subjects were followed prospectively to the end point of death or heart transplantation. Event-free survival was compared on the basis of the presence (group 1, n=266) or absence (group 2, n=203) of the Asp(298) variant. Event-free survival was significantly poorer in patients with the Asp(298) variant (percent event-free survival group 1 at 1/2/3 years=78/65/54; group 2=82/72/64, P=0.03). In subset analysis, the adverse impact of the Asp(298) variant was primarily in patients with nonischemic cardiomyopathy (group 1=82/73/63; group 2=87/79/71, P=0.03) and was not apparent among patients with ischemic heart disease (group 1=75/59/47; group 2=74/62/54, P=0.71). Conclusions-For patients with heart failure caused by systolic function, the Asp(298) variant of NOS3 is associated with poorer event-free survival, particularly in patients with nonischemic cardiomyopathy.